Key statistics
As of last trade, Emergent BioSolutions Inc (ER4:MUN) traded at 6.89, 81.33% above the 52 week low of 3.80 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.88 |
|---|---|
| High | 6.89 |
| Low | 6.88 |
| Bid | 6.86 |
| Offer | 6.99 |
| Previous close | 7.35 |
| Average volume | 83.43 |
|---|---|
| Shares outstanding | 52.10m |
| Free float | 50.69m |
| P/E (TTM) | 6.30 |
| Market cap | 424.62m USD |
| EPS (TTM) | 1.29 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 09:30 GMT.
More ▼
Announcements
- Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
- Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
- Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
- Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
- Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
- Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
- Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
- Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
- Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
More ▼
